Wellington Management Group LLP Has $28.67 Million Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

Wellington Management Group LLP raised its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 3,592.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 535,396 shares of the company's stock after buying an additional 520,898 shares during the quarter. Wellington Management Group LLP owned about 0.91% of Janux Therapeutics worth $28,665,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Barclays PLC lifted its holdings in shares of Janux Therapeutics by 496.5% in the third quarter. Barclays PLC now owns 174,061 shares of the company's stock valued at $7,907,000 after purchasing an additional 144,883 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in Janux Therapeutics by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock valued at $596,000 after buying an additional 1,095 shares during the last quarter. Chicago Capital LLC bought a new stake in Janux Therapeutics in the 4th quarter valued at approximately $230,000. abrdn plc acquired a new position in Janux Therapeutics during the 4th quarter worth approximately $3,430,000. Finally, Lester Murray Antman dba SimplyRich grew its stake in shares of Janux Therapeutics by 205.3% during the 4th quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company's stock worth $1,301,000 after acquiring an additional 16,351 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company's stock.

Janux Therapeutics Price Performance

NASDAQ JANX traded down $0.30 during trading on Wednesday, reaching $25.13. 543,953 shares of the company's stock were exchanged, compared to its average volume of 873,370. The business has a 50 day moving average price of $27.10 and a 200-day moving average price of $38.15. The stock has a market capitalization of $1.49 billion, a P/E ratio of -21.48 and a beta of 3.24. Janux Therapeutics, Inc. has a fifty-two week low of $22.48 and a fifty-two week high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the company's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $30.00, for a total value of $100,020.00. Following the transaction, the insider now owns 82,139 shares of the company's stock, valued at approximately $2,464,170. This represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ra Capital Management, L.P. purchased 110,206 shares of the company's stock in a transaction that occurred on Friday, March 7th. The shares were purchased at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the acquisition, the director now owns 10,141,287 shares in the company, valued at $314,582,722.74. The trade was a 1.10% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 8.10% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently commented on JANX shares. HC Wainwright reissued a "buy" rating and issued a $70.00 price objective on shares of Janux Therapeutics in a research report on Monday, March 3rd. Scotiabank cut their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research report on Friday, February 28th. Finally, Wedbush restated an "outperform" rating and set a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $95.25.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.